Online inquiry

IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15530MR)

This product GTTS-WQ15530MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TGM2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001323316.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7052
UniProt ID P21980
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15530MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4364MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ6511MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ12796MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ15373MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ4230MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ10435MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ1883MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ9994MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW